Total Funding
64
75
Total FundingPost-IPO Equity raised
Growth Score
-4 pts
Heat Score
3 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
3863
OS Therapies is a therapeutics company focused on the identification, development, and commercialization of treatments for osteosarcoma.
- Paul Romness: Chief Executive Officer and President
Robert G. Petit: Chief Medical & Scientific Officer for OS TherapiesPast Role: Advaxis, Vice President Clinical Operations and Medical Affairs
About the Company
OS Therapies operates as a clinical-stage therapeutic company focused on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors. It was launched to meet the significant unmet need for new treatments for cancers of the bone in kids and adults.The company has expanded the pipeline beyond
Osteosarcoma with OST-HER2 into other solid tumors with the same recurrence mechanism of action, including breast, esophageal, and lung cancer.
